Analysts Issue Forecasts for TSE:MDP FY2025 Earnings

Medexus Pharmaceuticals Inc. (TSE:MDP) – Equities research analysts at Leede Financial raised their FY2025 earnings estimates for shares of Medexus Pharmaceuticals in a note issued to investors on Wednesday, January 22nd. Leede Financial analyst D. Loe now expects that the company will post earnings of $0.29 per share for the year, up from their previous forecast of $0.20. Leede Financial currently has a “Strong-Buy” rating on the stock. The consensus estimate for Medexus Pharmaceuticals’ current full-year earnings is $0.16 per share. Leede Financial also issued estimates for Medexus Pharmaceuticals’ FY2027 earnings at $0.69 EPS and FY2028 earnings at $1.30 EPS.

MDP has been the topic of several other reports. Alliance Global Partners upgraded shares of Medexus Pharmaceuticals to a “strong-buy” rating in a report on Monday, December 23rd. Ventum Cap Mkts raised Medexus Pharmaceuticals to a “strong-buy” rating in a research report on Friday, January 17th. Raymond James raised shares of Medexus Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a C$4.00 price target on the stock in a research report on Wednesday, January 8th. Finally, Stifel Nicolaus lifted their target price on Medexus Pharmaceuticals from C$4.15 to C$4.50 in a research note on Tuesday, January 14th. One equities research analyst has rated the stock with a buy rating and five have given a strong buy rating to the company. According to data from MarketBeat, Medexus Pharmaceuticals currently has a consensus rating of “Strong Buy” and an average price target of C$5.58.

Medexus Pharmaceuticals Stock Down 5.9 %

TSE:MDP opened at C$4.47 on Thursday. The firm has a market capitalization of C$109.65 million, a P/E ratio of 89.40 and a beta of 1.96. Medexus Pharmaceuticals has a 12-month low of C$1.47 and a 12-month high of C$5.56. The stock’s fifty day simple moving average is C$3.14 and its 200-day simple moving average is C$2.69.

Medexus Pharmaceuticals Company Profile

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.